-
Mashup Score: 0
The REDUCE-IT EPA study suggests that EPA levels are the predominant driver of CV benefit observed in the REDUCE-IT trial and high EPA levels are associated with a reduced risk of a variety of CV events.
Source: PACE-CMECategories: CardiologistsTweet
-
Mashup Score: 3Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes - PACE-CME - 5 year(s) ago
COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.
Source: PACE-CMECategories: CardiologistsTweet-
Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes https://t.co/vp532mRZ5Z
-
Mechanistic underpinning of CV benefit observed with icosapent ethyl #CardioTwitter https://t.co/BTyl29M22M